2024 ESMO⼁消化道肿瘤领域LBA摘要公布，三项中国研究入选

2024年欧洲肿瘤内科学会（ESMO）将于9月13日至17日在西班牙巴塞罗那以线上线下结合形式举行。作为全球规模最大、学术水平最高、最具权威的临床肿瘤学会议之一，众多专家学者将展示肿瘤学领域的最新研究成果，共同推动肿瘤学科的全球发展。

近日，ESMO官方网站已正式公布Late-breaking abstracts（LBA，最新突破性摘要）标题。CCMTV小编带您一文速览消化系统肿瘤入选研究！

标题：POD1UM-303/InterAACT 2: Phase 3 Study of Retifanlimab With Carboplatin-Paclitaxel (C-P) in Patients (Pts) With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal (SCAC) Not Previously Treated With Systemic Chemotherapy (Chemo)

POD1UM-303/InterAACT 2：对未接受全身化疗的不可手术切除的局部复发性或转移性肛管鳞状细胞癌（SCAC）患者使用瑞特非尼单抗联合卡铂-紫杉醇（C-P）的III期研究

讲者：Sheela Rao (London, United Kingdom)

标题：Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study

对于中期肝细胞癌（HCC）患者的经动脉化疗栓塞术（TACE）联合或不联合乐伐替尼（len）+派姆单抗（pembro）的III期LEAP-012研究

讲者：Josep Llovet (Barcelona, Spain)

标题：Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): a randomized, open-label, phase 2/3 study (DUBHE-H-308)

Iparomlimab和tuvonralimab（QL1706）联合贝伐珠单抗和/或化疗作为一线（1L）治疗晚期肝细胞癌（aHCC）的随机、开放标签、2/3期研究（DUBHE-H-308）

讲者：秦叔逵教授 中国药科大学第一附属医院（南京天印山医院）

标题：Updated efficacy and safety data from IMbrave050: Phase 3 study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)

IMbrave050的疗效和安全性数据更新：对接受切除或消融的高危肝细胞癌（HCC）患者辅助阿替利珠单抗（atezo）+贝伐珠单抗（bev）与主动监测的III期研究

讲者：Adam Yopp (Dallas, United States of America)

标题：Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): results from the randomized phase II trial PANDAS/PRODIGE 44

术前改良FOLFIRINOX（mFOLFIRINOX）联合或不联合放化疗（CRT）治疗交界可切除胰腺癌（BRPC）的随机II期试验PANDAS/PRODIGE 44的结果

讲者：Aurélien Lambert (Nancy, France)

标题：Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

III期ALTN-AK105-III-02研究的主要结果：安罗替尼联合派安普利单抗对比索拉非尼一线（1L）治疗晚期肝细胞癌（aHCC）

讲者：周俭教授 复旦大学附属中山医院

标题：A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): final results from an intergroup trial of AGITG, TROG, EORTC and CCTG

可切除胃癌围手术期化疗联合或不联合术前放化疗的随机III期试验（AGITG TOPGEAR）：AGITG、TROG、EORTC和CCTG组间试验的最终结果

讲者：Trevor Leong (Melbourne, Australia)

标题：Modified FOLFOX plus/minus Nivolumab and Ipilimumab vs FLOT plus Nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Final Results of the IKF-AIO-Moonlight trial

改良FOLFOX联合或不联合纳武利尤单抗和伊匹木单抗与FLOT联合纳武利尤单抗在未经治疗的晚期或转移性胃或胃食管交界处腺癌患者中的疗效对比——IKF-AIO-Moonlight试验的最终结果

讲者：Sylvie Lorenzen (Munich, Germany)

标题：Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2

局部进展期dMMR结肠癌的新辅助免疫治疗：NICHE-2研究的3年无病生存率

讲者：Myriam Chalabi (Amsterdam, Netherlands)

标题：Randomized Phase III trial of Ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)

Ramucirumab联合TAS102（曲氟尿苷替匹嘧啶）对比TAS102单药治疗经多种前期治疗的转移性结直肠癌的随机III期试验：德国AIO的RAMTAS/IKF643试验（AIO-KRK-0316）

讲者：Stefan Kasper-Virchow (Essen, Germany)

标题：SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)

SOLARIS（Alliance A021703）：一项多中心、双盲、随机III期临床试验，研究维生素D联合标准化疗加贝伐珠单抗在未接受治疗的转移性结直肠癌（mCRC）患者中的疗效

讲者：Kimmie Ng (Boston, United States of America)

标题：Phase 3 study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)

SHR-1701联合化疗一线（1L）治疗HER2阴性胃/胃食管交界处腺癌（G/GEJA）的III期研究

讲者：彭智教授 北京大学肿瘤医院

标题：A randomized phase I/II study of second line treatment with liposomal irinotecan and S-1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer following gemcitabine-based chemotherapy

一项随机I/II期研究：伊立替康脂质体联合S-1对比伊立替康脂质体联合5-氟尿嘧啶二线治疗吉西他滨为基础化疗后转移性胰腺癌

讲者：Anne M. Gehrels (Amsterdam, Netherlands)